ARIAD Announces Pricing of Public Offering of Common Stock

  ARIAD Announces Pricing of Public Offering of Common Stock

  Financing to support global commercialization of Iclusig™ (ponatinib) and
    additional clinical development of its investigational targeted cancer

Business Wire

CAMBRIDGE, Mass. -- January 24, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of an
underwritten public offering of 15,307,000 shares of its common stock, at a
price to the public of $19.60 per share.The offering is expected to close on
or about January 29, 2013, subject to customary closing conditions. In
addition, ARIAD has granted the underwriters a 30-day option to purchase up to
2,296,050 additional shares of common stock to cover over-allotments, if any.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company,
Inc. are acting as joint book-running managers and underwriters for the
offering. BMO Capital Markets, Leerink Swann LLC, RBC Capital Markets, LLC and
UBS Investment Bank are acting as co-managers for the offering.

This funding is expected to enable ARIAD to support sales, marketing,
manufacturing and distribution of Iclusig™ (ponatinib). ARIAD anticipates that
this funding will also enable it to continue ongoing global development of its
other product candidates, including clinical trials, product and process
development activities, manufacturing and other activities; expand its
operations in Europe and other territories to prepare for future commercial
launch of products, if approved; continue discovery research efforts to add to
its pipeline of product candidates; and be used for other general corporate
purposes, including, but not limited to, repayment or refinancing of existing
indebtedness or other corporate borrowings, capital expenditures and possible

A shelf registration statement on Form S-3 relating to the public offering of
the shares of common stock described above was filed with the Securities and
Exchange Commission (the “SEC”) and is effective. A preliminary prospectus
supplement relating to the offering has been filed with the SEC, and a final
prospectus supplement relating to the offering will be filed with the SEC.
Copies of the final prospectus supplement and accompanying prospectus, when
available, may be obtained from the offices of J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717
(Telephone number 866-803-9204); the offices of Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717
(Telephone number 631-274-2806); or the offices of Jefferies & Company, Inc.,
Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New
York, NY, 10022, or by telephone at 877-547-6340, or by email at

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other


ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the
discovery, development and commercialization of medicines to transform the
lives of cancer patients. For more information about ARIAD, visit the
company’s website at

Forward-looking Statements

Certain of the statements made in this press release are forward looking, such
as those, among others, relating to our expectations regarding the expected
closing date of the public offering, the use of proceeds, our
commercialization and drug development plans and the sufficiency of funds for
the next two years. Actual results or developments may differ materially from
those projected or implied in these forward looking statements. Factors that
may cause such a difference include, without limitation, risks and
uncertainties related to whether or not we will be able to raise capital
through the sale of shares of common stock, market and other conditions, the
satisfaction of customary closing conditions related to the public offering
and the impact of general economic, industry or political conditions in the
United States or internationally. There can be no assurance that we will be
able to complete the public offering on the anticipated terms, or at all. You
should not place undue reliance on these forward looking statements, which
apply only as of the date of this press release. Additional risks and
uncertainties relating to the offering, ARIAD and our business can be found
under the heading "Risk Factors" in the filings that we periodically make with
the SEC and in the preliminary prospectus supplement related to the offering
filed with the SEC on the date hereof. In addition, the forward-looking
statements included in this press release represent our views as of the date
of this press release. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we specifically
disclaim any obligation to do so. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent to the date
of this press release.


ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
For Media
Liza Heapes, 617-621-2315
Press spacebar to pause and continue. Press esc to stop.